

# Coulter:Partners

## Top hires for VC & PE portfolio companies Q2-2022

### Search Highlights

This quarter's successful placements include:

- CEO, advanced machine learning tools, US
- CEO, drug discovery services, UK
- CEO, synthetic biology technologies, UK
- CEO Switzerland, in/outpatient services, Nordics
- Chief Scientific Officer, antibody-drug conjugates (ADCs), Denmark
- Chief Medical Officer, digital therapeutics, Sweden
- Chief Medical Officer, CNS diseases, Singapore
- Chief Business Officer, immuno-oncology and vaccines, Finland
- Chief Commercial Officer, contract research organisation, US
- Commercial Head Europe, A.I.-based neuro-diagnostics, Nordics
- Head Medicinal Chemistry, discovery tools, UK
- VP Operations, precision medicine technologies, US
- VP Molecular Pharmacology, RNA interference, US
- VP Clinical Development, RNA therapeutics, US
- VP Finance, immuno-oncology, Switzerland
- Investment Partner, private equity investor, France

Newly opened projects include:

- CEO, oncology devices, Italy
- CEO, diagnostics technology, UK
- CEO, immuno-oncology, Belgium
- Chief Business Officer, gene therapies, Netherlands
- Chief Medical Officer, radiopharmaceuticals, China
- Chief Medical officer, digital therapeutics, France
- Chief Financial Officer, genomic technologies, US
- Chief Commercial Officer US, molecular cartography, Germany
- Chief Technology Officer, contract development organisation, US
- SVP Research, gene delivery technologies, US
- VP Intellectual Property, protein degradation technology, UK
- General Manager UK, digital devices and therapeutics, US
- Board Director, advanced reagents, Sweden
- Chair, active pharmaceutical ingredients, Switzerland

### Themes

Areas of focus this quarter include, but are not limited to:

- Genomics
- Drug delivery
- In/ outpatient services
- A.I. diagnostics
- Vaccines
- CNS
- Synthetic biology
- Immunology/ Inflammation
- APIs
- Digital therapeutics
- Contract manufacturing
- Gene therapies

[www.coulterpartners.com](http://www.coulterpartners.com)